INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22201, 3613, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22202, 3614, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22203, 9068, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22204, 9069, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22205, 9070, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22206, 19895, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22207, 19897, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22208, 22980, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22209, 22981, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22210, 22982, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22211, 25885, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22212, 25886, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22213, 25887, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22214, 25888, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22215, 25889, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22216, 25890, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22217, 25891, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22218, 25892, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22219, 26305, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22220, 26306, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22221, 26307, 'Repaglinide', 'Kidney Diseases', 'Patients with severely reduced renal function treated with repaglinide had elevated plasma drug concentrations.  Patients with type 2 diabetes who have severe renal function impairment should initiate repaglinide therapy with the 0.5 mg dose and subsequently, patients should be carefully titrated.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22222, 26114, 'Rimantadine', 'Liver Diseases', 'Rimantadine is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from rimantadine due to decreased drug clearance.  Therapy with rimantadine should be administered cautiously in patients with liver disease.  One-half the usual dosage is recommended for patients with severe hepatic dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22223, 26408, 'Rimantadine', 'Liver Diseases', 'Rimantadine is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from rimantadine due to decreased drug clearance.  Therapy with rimantadine should be administered cautiously in patients with liver disease.  One-half the usual dosage is recommended for patients with severe hepatic dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22224, 29409, 'Rimantadine', 'Liver Diseases', 'Rimantadine is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from rimantadine due to decreased drug clearance.  Therapy with rimantadine should be administered cautiously in patients with liver disease.  One-half the usual dosage is recommended for patients with severe hepatic dysfunction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22225, 26114, 'Rimantadine', 'Kidney Diseases', 'Rimantadine and its metabolites are excreted by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from rimantadine due to decreased drug clearance.  Therapy with rimantadine should be administered cautiously in patients with renal impairment.  One-half the usual dosage is recommended for patients with severe renal dysfunction (CrCl <= 10 mL/min).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22226, 26408, 'Rimantadine', 'Kidney Diseases', 'Rimantadine and its metabolites are excreted by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from rimantadine due to decreased drug clearance.  Therapy with rimantadine should be administered cautiously in patients with renal impairment.  One-half the usual dosage is recommended for patients with severe renal dysfunction (CrCl <= 10 mL/min).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22227, 29409, 'Rimantadine', 'Kidney Diseases', 'Rimantadine and its metabolites are excreted by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from rimantadine due to decreased drug clearance.  Therapy with rimantadine should be administered cautiously in patients with renal impairment.  One-half the usual dosage is recommended for patients with severe renal dysfunction (CrCl <= 10 mL/min).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22228, 26114, 'Rimantadine', 'Epilepsy', 'Seizures have been reported in a few patients with a history of seizure disorders who were not receiving anticonvulsant medication while taking rimantadine.  Therapy with rimantadine should be administered cautiously in patients with epilepsy or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22229, 26408, 'Rimantadine', 'Epilepsy', 'Seizures have been reported in a few patients with a history of seizure disorders who were not receiving anticonvulsant medication while taking rimantadine.  Therapy with rimantadine should be administered cautiously in patients with epilepsy or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22230, 29409, 'Rimantadine', 'Epilepsy', 'Seizures have been reported in a few patients with a history of seizure disorders who were not receiving anticonvulsant medication while taking rimantadine.  Therapy with rimantadine should be administered cautiously in patients with epilepsy or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22231, 11915, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22232, 12330, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22233, 12339, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22234, 20361, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22235, 20363, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22236, 24546, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22237, 24547, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22238, 26052, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22239, 26053, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22240, 26055, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22241, 26056, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22242, 26057, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22243, 26058, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22244, 26059, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22245, 26060, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22246, 26061, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22247, 26067, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22248, 26068, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22249, 29391, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22250, 29400, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22251, 29402, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22252, 29406, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22253, 29407, 'Ribavirin', 'Anemia', 'Oral ribavirin may cause anemia.  The decrease in hemoglobin generally occurs within 1 to 2 weeks after initiation of therapy and stabilizes by week 4.  Because significant anemia may adversely affect cardiac function, oral ribavirin should not be used in patients with severe anemia of any etiology or a history of serious or unstable heart disease.  It should also be avoided in patients with hemoglobinopathies such as thalassemia or sickle- cell anemia.  Therapy with oral ribavirin may be administered cautiously in patients with stable heart conditions.  Both the hemoglobin level and cardiovascular status must be closely monitored.  A permanent dosage reduction is required in these patients if the hemoglobin decreases by >= 2 g/dL during any 4- week period.  If, after 4 weeks on the reduced dosage, the hemoglobin remains < 12 g/dL, therapy should be discontinued.  The drug should also be withdrawn if cardiovascular status deteriorates.  For all patients, a dosage reduction is recommended when hemoglobin is < 10 g/dL.  If hemoglobin falls below 8.5 g/dL, oral ribavirin should be permanently discontinued.  In clinical trials, hemoglobin values generally returned to baseline 4 to 8 weeks after cessation of therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22254, 11915, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22255, 12330, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22256, 12339, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22257, 20361, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22258, 20363, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22259, 24546, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22260, 24547, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22261, 26052, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22262, 26053, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22263, 26055, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22264, 26056, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22265, 26057, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22266, 26058, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22267, 26059, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22268, 26060, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22269, 26061, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22270, 26067, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22271, 26068, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22272, 29391, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22273, 29400, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22274, 29402, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22275, 29406, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22276, 29407, 'Ribavirin', 'Lung Diseases', 'The use of aerosolized ribavirin has been associated with deterioration in pulmonary function, most significantly in patients with chronic obstructive pulmonary disease or asthma.  Respiratory status should be monitored in all patients receiving aerosolized ribavirin, but in particular, patients with underlying respiratory disorders.  Therapy should be stopped if sudden deterioration occurs, and reinstituted only with extreme caution and consideration of concomitant bronchodilator therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22277, 11915, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22278, 12330, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22279, 12339, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22280, 20361, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22281, 20363, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22282, 24546, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22283, 24547, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22284, 26052, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22285, 26053, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22286, 26055, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22287, 26056, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22288, 26057, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22289, 26058, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22290, 26059, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22291, 26060, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22292, 26061, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22293, 26067, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22294, 26068, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22295, 29391, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22296, 29400, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22297, 29402, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22298, 29406, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22299, 29407, 'Ribavirin', 'Kidney Diseases', 'Orally administered ribavirin is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney.  In patients with creatinine clearance between 10 and 30 mL/min, the mean area under the concentration-time curve has been shown to be three times greater than that in patients with normal renal function, presumably due to decreased clearance of the drug.  Therapy with oral ribavirin should be administered cautiously in patients with creatinine clearance below 50 mL/min.  Dosage adjustments may be necessary.  The drug is not recommended for use in patients with severe renal impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (22300, 3302, 'Resorcinol (topical)', 'Hypothyroidism', 'The use of resorcinol topical has been associated with producing goiter in patients with abraded skin.  Therapy with resorcinol topical should be administered cautiously in patients with hypothyroidism.  Monitoring thyroid function is recommended in these patients.', '2', '', 'DDInter', 0);
